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Role of TGF-1 in renal parenchymal scarring following child- responsible for 10 to 24% of all children entering end-
hood urinary tract infection. stage renal failure (ESRF) in Europe [1]. Reported risk
Background. Significant variability exists in the outcome of factors for the development of RPS following UTI in-renal parenchymal inflammation following urinary tract infec-
clude vesico-ureteric reflux (VUR) [2], young age [3],tion (UTI) in childhood as some children experience renal
delayed treatment [4], and recurrent infection [5]. Recentparenchymal scarring (RPS) while others do not scar. Since
TGF-1 is pro-fibrotic, we examined the role of this cytokine reports have suggested that children with the DD angio-
in RPS following UTI. tensin-converting enzyme (ACE) genotype also may
Methods. Five polymorphisms of the TGF-1 gene were have an increased risk of scarring [6].investigated as well as the relationship between these polymor-
Inflammatory mediators including cytokines, toxic me-phisms and TGF-1 production by peripheral blood mono-
nuclear cells (PBMC) in vitro. DNA was isolated from 91 tabolites and enzymes released from leukocyte infiltrates
children shown to have developed RPS, 43 children with no initiate the structural damage to the parenchyma leading
evidence of scarring (NS) following UTI, and 171 healthy con- to RPS [7–10]. Urinary interleukin (IL)-1 [11], IL-6 [12],trols. Genotyping was performed by restriction fragment length
and IL-8 levels [12] are increased in those children whopolymorphism (RFLP). PBMC were isolated from a subgroup
develop RPS, where it has been suggested that renal pa-of 24 patients from the total population. Cells were stimulated
with LPS  PMA  PHA and then TGF-1 production was renchymal cells produce local inflammatory mediators
determined by ELISA. in response to invading pathogens. In vivo, mouse kidney
Results. Comparing the NS with the RPS group, there was cells have been demonstrated to express increasedan increase in the 800 GA genotypes (18.6 vs. 7.4%, P 
amounts of mRNA for interleukin-4 (IL-4), IL-10, tumor0.05; 2) and the Leu10→Pro CT (62.8 vs. 41.5%, P  0.021),
and a decrease in the 509 TT genotype (0.0 vs. 8.5%, P  necrosis factor- (TNF-) and transforming growth
0.049). PBMC TGF-1 production was higher in those patients factor-1 (TGF-1) during acute Escherichia coli pyelo-
with the 800 GG compared to those with a GA genotype nephritis [13].stimulation index [stimulated/unstimulated TGF-1 levels were
Transforming growth factor-1 plays a crucial role in1.54 interquartile range (IQR) 1.42 to 1.75 vs. 1.19, IQR 0.94
promoting extracellular matrix (ECM) deposition andto 1.51, P  0.031].
Conclusions. There is an association between the TGF-1 fibrosis, leading to loss of functional renal tissue [14]. A
800 GA, 509 TT and Leu10→Pro CT genotypes and the number of factors known to be important in the patho-
presence or absence of RPS. The low TGF-1 producer status genesis of human renal disease also result in increasedof the800 GA genotype may protect against the development
TGF-1 levels, including hypoxia, hyperglycemia, auto-of a pro-fibrotic pathology.
antibodies, immune complex deposition, platelet-derived
growth factor (PDGF), and TGF-1 itself [14]. TGF-1
leads to ECM deposition through increased synthesis ofUrinary tract infection (UTI) is a common bacterial
infection of childhood. Renal parenchymal scarring (RPS) matrix proteins such as collagens, fibronectin, proteogly-
is the most important complication of infection, and is can, and cell surface integrins [14], at the same time
decreasing matrix protein degradation by suppression of
protease expression and increased production of prote-Key words: pediatric nephropathy, transforming growth factor-1,
polymorphisms, 800 GA genotype, fibrosis, bacterial infection. ase inhibitors such as plasminogen activator inhibitor
type 1 (PAI-1) or tissue inhibitor of matrix metallopro-Received for publication December 29, 2000
teinases (TIMPs) [14]. All of these factors support theand in revised form August 17, 2001
Accepted for publication August 27, 2001 hypothesis that TGF-1 is an important factor in the
pathogenesis of RPS following UTI. Variable constitu- 2002 by the International Society of Nephrology
61
Cotton et al: RPS following childhood UTI62
Table 1. Amplimers, allele specific oligonucleotides and reaction conditions for polymorphisms of
the transforming growth factor-1 (TGF-1) gene
Annealing
Size N Mg2 temperature
Position Amplimers (5 to 3) bp cycles mmol/L C
800 F: ACAGTTGGCACGGGCTTTCG 388 32 3.5 60
R: TCAACACCCTGCGACCCCAT
509 F: CAGTAAATGTATGGGGTCGCAG 153 32 3.0 55
R: GGTGTCAGTGGGAGGAGGG
c10 F: CTCCGGGCTGCGGCTGCGGC 199 35 2.5 55
R: CGGCACCTCCCCCTGGCTCG
c25 F: GCTGCTGCTACCGCTGCTGT 177 32 2.5 55
R: GGCACCTCCCCCTGGCTG
c263 F: CCTTTCCTGCTTCTGATGGCCA 119 32 4.0 60
R: CTCCATCCAGGCTACAAGGCTCA
Abbreviations are: F, forward primer; R, reverse primer; c, codon; bold letter, forced base change.
tive or induced expression of TGF-1 protein could oc- indicative of RPS on the DMSA scan), a micturating
cur as a consequence of variability in the TGF-1 gene, cystourethrogram was also performed. The group was
which in turn could be associated with differential effects subdivided into those who had developed RPS and those
on cellular growth or ECM deposition leading to RPS. without scarring (NS).
Seven polymorphisms have been described in the Children were excluded from the study if they had ob-
TGF-1 gene in the coding region and 2181 bp upstream structive uropathy, external malformations of the ge-
[15]. These are at positions 988, 800, and 509 from nito-urinary tract, neuropathic bladder, or where DMSA
the first transcribed nucleotide: one in the non-translated changes were suggestive of renal hypoplasia [small kid-
region at position 72; two in the signal peptide se- ney(s) with smooth parenchymal outlines and no focal
quence Leu10→Pro, Arg25→Pro; and one in the region of changes].
the gene coding for the precursor part of the peptide
Children and adults with no previous history of UTI
not present in the active form, Thr263→Ile. T- and
or renal disease acted as control subjects. Ethical ap-B-lymphocytes, natural killer (NK) cells and lymphokine
proval for the study was granted by the Salford andactivated killer (LAK) cells produce TGF-1 in vitro
Trafford Local Research Ethics Committee.[16–19]. PBMC produce latent TGF-1 in vitro (3 to
15 ng/mL), which can be enhanced by treatment with
DNA extraction and TGF-1 genotypingphytohemagglutinin-P (PHA) and phorbol myristate ace-
Venous blood was collected in EDTA coated tubes.tate (PMA) [20]. Awad et al have suggested that TGF-1
DNA was prepared from whole blood using a salting outpolymorphisms may differentially regulate TGF-1 pro-
duction by PBMC in vitro [21]. process. Specific oligonucleotide primers were designed
Our study was designed to investigate the genetic con- based on the published TGF-1 genomic sequence [22],
tribution of TGF-1 in RPS following UTI by (a) exam- [23]. Polymerase chain reaction (PCR) amplification for
ining the genotype frequencies for polymorphisms of the each polymorphism was performed in a total reaction
TGF-1 gene at positions800 and509, and at Leu10→ volume of 20 	L with 100 ng DNA, 1 
 NH2SO4 PCR
Pro, Arg25→Pro and Thr263→Ile in patients with and with- buffer, 0.5 	mol/L of each primer, 10% dimethyl sulfox-
out RPS following urinary tract infection, and (b) to ide (DMSO), 0.75 mmol/L of each desoxynucleoside tri-
examine the relationship between these polymorphisms phosphate (dNTP), and 0.5 units Taq polymerase, with
and TGF-1 production by PBMC in vitro. varying concentrations of Mg2 (primers and reaction con-
ditions are in Table 1). The cycling conditions were: 94C
METHODS for three minutes, followed by 32 or 35 cycles of 94C
for one minute, variable annealing temp for one minute,Study subjects
72C for one minute, followed by a terminal extensionChildren with a proven history of UTI (pure growth
step of 72C for five minutes. The number of cycles andof 105 organisms/mL on a clean catch, catheter or su-
annealing temperatures are shown in Table 1. Genotyp-prapubic specimen of urine) in association with recog-
ing was performed by restriction fragment length poly-nized symptoms of UTI were retrospectively included
morphism (RFLP) analysis. The Leu10→Pro and Thr263→as study subjects. All underwent a DMSA scan at least
Ile polymorphisms do not create or remove an enzymesix weeks post-infection and where clinically indicated
(age under 2 years, or evidence of parenchymal damage restriction site, so a base change was forced in the primer
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Table 2. Genotyping restriction enzymes, conditions and measurement of TGF-1. All samples were measured in
polymorphic base detection
duplicate using an enzyme-linked immunosorbent assay
Digest (ELISA), which has previously been described [24]. To
Restriction enzyme temperature Base required
control for interassay variation, an internal WHO stan-Position recognition site C for digestion
dard (NIBSC no. 89/514) TGF-1 preparation was used
800 Tai 1 65 G
on every plate. TGF-1 levels were calculated by refer-509 Bsu36I 37 C
c10 Not 1 37 C ence to a standard curve in pg/mL. A stimulation index
c25 Bgl 1 37 G was calculated by division of TGF-1 levels producedc263 BsrBR1 37 T
by stimulated cells by TGF-1 levels produced by un-
stimulated cells isolated from the same patient.
Statisticsto create an enzyme restriction site. Enzymes and condi-
Genotype and allele frequencies (ratio of test geno-tions are shown in Tables 1 and 2.
type/allele to total genotypes/alleles) were compared us-
Production of TGF-1 by PBMC ing the 2 test; Yates correction was applied where neces-
sary. The Kruskal-Wallis test was used to compareTo investigate the production of TGF-1 by PBMC
in vitro, a modified version of the methodology of Lucas differences in TGF-1 production by different TGF-1
et al was followed [20], as in our pediatric study it was genotypes. Where there were only two genotypes, for
necessary to modify the Lucas protocol to incorporate example, the 800 polymorphism, TGF-1 production
the use of fewer PBMCs. This required supplementation was compared using the Mann-Whitney U test. The
of the cell culture medium with 10% fetal calf serum Mann-Whitney U test was used to compare TGF-1
(FCS) to maintain cell viability over the five-day culture production between RPS and NS patient groups. Statisti-
period. PBMC were isolated from individual subjects by cal significance was taken as a value of P  0.05.
centrifugation over a Lymphoprep (Life Technologies
Ltd, Paisley, UK) gradient and cells were resuspended
RESULTSin RPMI 1640 medium (Sigma-Aldrich Company Ltd,
Dorset, Poole, UK) supplemented with 10% FCS (Sigma), Characteristics of subjects and controls
1% penicillin-streptomycin solution (Sigma) and 1% glu- The total number of subjects genotyped for TGF-1
tamine (Sigma). PBMC were cultured at 1
 106 cells/mL polymorphisms was 308: 94 patients with a history of
in 5% CO2 at 37C in a humidified incubator. Experi- UTI with resultant RPS, 43 with a history of UTI with
ments were set up in 96-well round-bottom cell culture no resultant scarring (NS), and 171 control subjects. Both
plates with 2 
 105 cells in each well. PBMC were stimu- the UTI and control subjects were predominantly Cauca-
lated in triplicate with 10 	g/mL PHA (Sigma, L9132),
sian (95.5 vs. 95.9%, respectively). The gender distribu-
50 ng/mL PMA (Sigma, P148) and 1 ng/mL lipopolysac-
tion was similar in the RPS (64.3% female, 35.7% male)
charide (LPS; 0113:H10; Quadratech, Surrey, UK). Pre-
and NS (60.0% female, 40.0% male) groups. It was simi-liminary experiments of three and five days of PBMC
lar also between the entire UTI patient group (64.8%culture had revealed optimal latent TGF-1 production
female, 35.2% male) and the control subjects (54.1%at five days, which was significantly higher than at three
female, 45.9% male). There was a higher incidence ofdays (P 0.01, Mann-Whitney U test). Maximal TGF-1
VUR in the RPS group when compared with the NSproduction by PBMC at five days under similar condi-
group (75.6% vs. 23.3%, P  0.0001, 2, respectively).tions had been reported previously by Lucas et al [20]
Median age at first UTI was 3.0 years in the RPS andand Awad et al [21].
1.6 years in the NS patients. The DMSA scan was per-The same batch of FCS (Sigma lot no. 38H3372) was
formed at a median time of 11.5 weeks post-infectionused in all experiments; this incorporated the use of FCS
(range 6 to 52 weeks). Within the patient group, 8 chil-that had been batch tested for its ability to support the
dren had significant proteinuria (early morning protein:maximum stimulated TGF-1 level when compared to
creatinine ratio 250 mg/mmol) and 9 had chronic renalunstimulated levels. All experiments were performed in
insufficiency (predicted GFR 50 mL/min/1.73 m2).triplicate, and unstimulated PBMC acted as matched
controls. Cell culture supernatants were harvested and
Genotype distributionstored at 20C prior to assaying.
The distribution of genotypes and alleles for the differ-Transforming growth factor-1 produced by PBMC
ent polymorphisms in patients and control subjects arewas in a latent form, as cell culture supernatants were
shown in Table 3. No significant deviation from the Hardy-negative without acid urea activation, similar to the find-
ings of Lucas et al [20]. Acid urea activation enabled Weinberg expectation was observed. The genotype fre-
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Table 3. Distribution of TGF-1 Genotypes and alleles in the renal parenchymal scarring (RPS), non-scarring (NS) and control groups
Control P value
TGF-1 polymorphism RPS patients NS patients subjects RPS vs. NS
800
GG 91.5 (86) 81.4 (35) 81.9 (140)
GA 7.4 (7) 18.6 (8) 16.4 (28) 0.050
AA 1.1 (1) 0.0 (0) 1.8 (3)
G:A 0.95:0.05 0.91:0.09 0.90:0.10
509
CC 42.6 (40) 37.2 (16) 44.4 (76)
CT 48.9 (46) 62.8 (27) 46.2 (79)
TT 8.5 (8) 0.0 (0) 9.4 (16) 0.049
C:T 0.67:0.33 0.69:0.31 0.68:0.32
Leu10→Pro
T/T 39.4 (37) 30.2 (13) 42.7 (73)
T/C 41.5 (39) 62.8 (27) 42.1 (72) 0.021
C/C 19.1 (18) 7.0 (3) 15.2 (26)
C:T 0.60:0.40 0.62:0.38 0.64:0.36
Arg25→Pro
G/G 88.3 (83) 81.4 (35) 84.2 (144)
G/C 10.6 (10) 18.6 (8) 14.6 (25)
C/C 1.1 (1) 0.0 (0) 1.2 (2)
G:C 0.94:0.06 0.91:0.09 0.92:0.08
Thr263→Ile
C/C 94.7 (89) 90.7 (39) 94.2 (161)
C/T 5.3 (5) 9.3 (4) 5.8 (10)
T/T 0.0 (0) 0.0 (0) 0.0 (0)
C:T 0.97:0.03 0.95:0.05 0.97:0.03
Values are shown as % (N).
quencies in the control group were similar to existing comprised 14 RPS (9 female, 5 male) and 10 NS (6
published data [15]. female, 4 male) patients. All children were free of infec-
Genotype and allele frequencies did not differ signifi- tion at the time of sampling. Seventeen children were
cantly between the total patient group with a history of not receiving any medication, 5 were receiving antibiotics
UTI and control subjects. In addition, they did not differ and 2 enalapril. Three children had significant proteinuria
significantly between those children who had VUR and (early morning protein:creatinine ratio 250 mg/mmol)
those who did not. and chronic renal insufficiency (predicted GFR50 mL/
The genotype distribution of the 800, 509 and min/1.73 m2). The genotype distribution of the TGF-
Leu10→Pro polymorphisms was different between the polymorphisms was representative of the larger study
RPS and NS groups (Table 3). There was a trend for an cohort. There was a trend for an increase in the 800
increase in the 800 GA (P  0.050) and a significant GA (25.0 vs. 15.4%, P 0.548) and a significant increase
increase in the Leu10→Pro CT (P  0.021) genotypes in in the Leu10→Pro CT genotypes (75.0 vs. 33.3%, P 
the NS group when compared to the RPS group. For 0.041) in the NS group when compared to the RPS group.
the509 polymorphism, there was a significant decrease For the 509 polymorphism, there was a trend for a
in the TT (P  0.049) genotype in the NS group when decrease in the TT genotype (0.0 vs. 8.3%, P  0.307)
compared to the RPS group. At the allelic level no sig- in the NS group when compared to the RPS group.
nificant difference was observed between the two groups.
Peripheral blood mononuclear cell TGF-1 produc-
A sub-analysis in the high-risk group of those children
tion was significantly higher in those patients with a GGage four years or younger at first UTI was undertaken.
800 TGF-1 genotype than those with a GA genotype,This group incorporated 48 children with RPS and 30
with a median stimulation index (stimulated/unstimu-NS children. Comparing the NS with the RPS group the
lated TGF-1 levels) of 1.54 [interquartile range (IQR)significant increase in the 800 GA genotype (20.0 vs.
1.42 to 1.75] versus 1.19 (IQR 0.94 to 1.51), respectively2.1%, P  0.007) was more marked and the Leu10→
(P  0.031, Mann-Whitney U test; Fig. 1). The stimula-Pro CT genotype (70.0 vs. 42.6%, P  0.019) remained
tion index for the 800 GG genotype represented acomparable, whereas the association with the 509 TT
median production of 1073 pg/mL (stimulated unstim-genotype was not apparent.
ulated levels) versus the GA genotype of 312 pg/mL
PBMC TGF-1 production (stimulated  unstimulated levels). No association was
observed between the other TGF-1 genotypes andTransforming growth factor-1 production by PBMC
isolated from a total of 24 patients was measured. These TGF-1 production.
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Fig. 1. Transforming growth factor-1 (TGF-1) production by pe-
ripheral blood mononuclear cells (PBMC); a comparison of TGF-1 Fig. 2. TGF-1 production by PBMC; a comparison of the renal paren-
800 genotype. TGF-1 production was significantly higher in those chymal scarring (RPS) versus the no scarring (NS) groups of children.
patients with a GG 800 TGF-1 genotype than those with a GA There was no significant difference in PBMC TGF-1 production be-
genotype. The thick horizontal bar denotes the median, and whiskers tween those patients who had not developed RPS (NS) and those who
show the interquartile range. P  0.031 by the Mann-Whitney U test. had developed RPS. The thick horizontal bar denotes the median, and
whiskers show the interquartile range. P  0.198 by the Mann-Whitney
U test.
There was no difference in PBMC TGF-1 production
between those patients who had not developed RPS (NS)
less protein secretion. This is of even greater importanceand those who had developed RPS [median 1.46 (IQR
when one considers that TGF-1 is capable of autoregu-1.26 to 1.58) vs. 1.54, (IQR 1.36 to 1.75), respectively,
lation of its own mRNA expression through AP-1 [29].P  0.198, Mann-Whitney U-test; Fig. 2).
Therefore, genetic variability in this transcription factor
binding site may be important and may make the GA
DISCUSSION 800 genotype protective against the development of a
TGF-1 genotype and RPS pro-fibrotic pathology.
The frequency of the TT 509 genotype was de-The association between 800 GA, 509 TT and
creased in the NS group when compared to the RPSTGF-1 Leu10→Pro CT genotypes and renal parenchy-
group, although this association was lost in the highermal outcome following UTI is supportive of a role for
risk4-year-old age group. This polymorphism is withinTGF-1 in the pathogenesis of RPS.
the promoter region and lies several bases from a consen-The GA 800 genotype was more frequent in the NS
sus DR1 or DR5 nuclear hormone binding site [30],group when compared to the RPS group. This increase
where ligands for nuclear hormone receptors have beenwas even more marked in those children aged 4 years or
shown to regulate TGF-1 production in vitro [31].less. The 800 polymorphism occurs within a consensus
The Leu10→Pro CT genotype was found more fre-cAMP-resistant binding protein (CREB) half-site [25].
quently in the non-scarring group when compared to theThe presence of the A allele deletes an activated protein-1
RPS group, with the association remaining constant in(AP-1) transcription factor binding site [25]. Therefore,
the higher risk4 years of age group. This polymorphismthe A allele is expected to have reduced affinity for the
is located in the signal peptide sequence that is cleavedCREB family of transcription factors [25]. The influence
from the TGF-1 precursor at codon 29 [15]. The signalof cytokines on cellular function occurs ultimately
sequence allows export of newly synthesized proteinthrough their ability to alter gene transcription through
across the membranes of the endoplasmic reticulum.nuclear transcription factors such as the AP-1 site. AP-1
Within this signal peptide sequence, the Leu10→Pro poly-is a phorbol ester-induced transcription factor [26],
morphism codes for amino acid residues in the hy-formed by a complex of Jun and Fos nuclear oncoprot-
drophobic core. However, since Leu and Pro are apolar,eins [27]. The c-jun gene is positively autoregulated by
the polymorphism should not affect the function of theits gene product Jun/AP1 protein [28]. Therefore, the
signal peptide [15]. Therefore, it is difficult to postulateabsence of a TGF-1 AP-1 site at position 800 for
its function in the development of RPS following UTI.those individuals with a GA genotype may result in a
reduced expression of TGF-1 mRNA and ultimately However, the TGF-1 polymorphisms are strongly asso-
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ciated with one another. The similar allele frequencies duce TGF-1 whether or not they developed RPS. How-
ever, the genotype frequencies in the larger genotypicand strong positive linkage disequilibrium between the
study are such that the GA 800 genotype is increased72 and Arg25→Pro polymorphism reflect complete as-
in the NS group. One might expect the NS group to besociation and make separate investigation of each poly-
lower TGF-1 producers than the RPS group, as themorphism unnecessary [15]. To a lesser extent the509,
GA 800 genotype is associated with lower levels ofLeu10→Pro and Arg25→Pro are linked with one another.
production. This may have not been observed in thisGiven the strong linkage disequilibrium between the
study due to the small number of patients with the GATGF-1 polymorphisms, it may be a complex haplotype
800 genotype (2 in the RPS and 3 in the NS groups).that ultimately leads to a predisposition to RPS following
The low frequency of the GA 800 genotype in theUTI.
general population and the patient groups requires aIn discussing any genotypic association with RPS, one
significantly larger study to be undertaken before the fullhas to acknowledge that the optimal timing of the DMSA
function of this polymorphism in RPS can be establishedscan post-infection is still contentious. In keeping with
with certainty.current United Kingdom guidelines for the investigation
While our study investigated the role of TGF-1 inof children following proven urinary tract infection [32],
relation to the risk of RPS following UTI, other riskpatients underwent their DMSA scan at a median time
factors have been suggested. Clinically, age is generallyof 11.5 weeks post-infection and those with abnormalities
considered to be the most important risk factor, withwere classified as having RPS. While large series studies
young children being at greatest risk [3]. Scarring is com-have shown that DMSA scan abnormalities detected at
monly associated with vesico-ureteric reflux, with thea similar time-point post-infection persist on long-term
most severe damage occurring in those with the morefollow-up [33], others have found a number to undergo
severe grades of reflux [2].resolution, the implication being that the changes re-
Experimentally, investigators have sought to examineflected acute parenchymal inflammation rather than scar-
the role of cytokines and predisposition to renal paren-ring [34]. It is possible, therefore, that a small number
chymal scarring. IL-1 [11], IL-6 [12] and IL-8 [12] pre-of children classified as having RPS may have seen reso-
viously have been found in increased concentrations inlution of their DMSA scan changes with additional fol-
the urine of children with acute pyelonephritis. Persistentlow-up.
DMSA changes at one year of follow up, reflecting renal
scarring, have been observed only in children with in-TGF-1 production by PBMC and TGF-1 genotype
creased urine IL-6 levels during the acute phase of acute
This study also found an association between the pyelonephritis [12].
TGF-1 800 genotype and production in vitro. While Inflammatory cytokines such as IL-1, IL-6 and IL-8
this finding represents a small number of patients and may represent the presence of the immune response to
thus few individuals of a TGF-1 800 GA genotype, infection, which may result in renal scarring. TGF-1
it is potentially exciting because it shows a genotypic expression may follow this initial response and may be
association where a polymorphism may control TGF-1 pivotal in excessive ECM deposition and thus scarring.
levels through a transcriptional mechanism. As discussed There is evidence to suggest that TGF-1 is involved
previously, the polymorphism occurs within an AP-1 during disturbances to the urinary tract and subsequent
binding site, which has been postulated to affect the renal scarring. For example, during obstructive nephrop-
expression of TGF-1 protein. In this study the GA athy, there is an increase in TGF-1 production [35].
genotype and thus deletion of the AP-1 binding site It may be the case that TGF-1 has a role in the
resulted in individuals carrying this genotype producing pathogenesis of RPS at both a molecular and genetic
less TGF-1 than those with a GG genotype. There was level when evidence from animal models and the data
no other association between any of the other TGF-1 presented in this paper are considered. The results of
genotypes and production in vitro, and we could not this study therefore lend support to the hypothesis that
confirm the link between the Arg25→Pro polymorphism genetic variation in the TGF-1 gene predisposes to RPS
and level of production, as reported by Awad et al [21]. following UTI.
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